Cargando…

Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience

BACKGROUND: Despite all the scientific progress that has been made on understanding the disease, prognosis for patients with relapsed and refractory Hodgkin's lymphoma remains poor and the treatment is palliative in the majority of the cases. Thus, the aim of this study was to present the resul...

Descripción completa

Detalles Bibliográficos
Autores principales: Rocha, Talita Máira Bueno da Silveira da, Fortier, Sergio Costa, Fischer, Thais Rodrigues da Cunha, Perini, Guilherme Fleury, Gaiolla, Rafael Dezen, Fogliatto, Laura, Delamain, Marcia Torresan, Costa, Andressa Fragoso da, Castro, Nelson Siqueira de, Barretos, Wolney Gois, Souza, Cármino Antonio de, Buccheri, Valéria, Chiattone, Carlos Sérgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Hematologia e Hemoterapia 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567422/
https://www.ncbi.nlm.nih.gov/pubmed/28830600
http://dx.doi.org/10.1016/j.bjhh.2017.03.008
_version_ 1783258729884418048
author Rocha, Talita Máira Bueno da Silveira da
Fortier, Sergio Costa
Fischer, Thais Rodrigues da Cunha
Perini, Guilherme Fleury
Gaiolla, Rafael Dezen
Fogliatto, Laura
Delamain, Marcia Torresan
Costa, Andressa Fragoso da
Castro, Nelson Siqueira de
Barretos, Wolney Gois
Souza, Cármino Antonio de
Buccheri, Valéria
Chiattone, Carlos Sérgio
author_facet Rocha, Talita Máira Bueno da Silveira da
Fortier, Sergio Costa
Fischer, Thais Rodrigues da Cunha
Perini, Guilherme Fleury
Gaiolla, Rafael Dezen
Fogliatto, Laura
Delamain, Marcia Torresan
Costa, Andressa Fragoso da
Castro, Nelson Siqueira de
Barretos, Wolney Gois
Souza, Cármino Antonio de
Buccheri, Valéria
Chiattone, Carlos Sérgio
author_sort Rocha, Talita Máira Bueno da Silveira da
collection PubMed
description BACKGROUND: Despite all the scientific progress that has been made on understanding the disease, prognosis for patients with relapsed and refractory Hodgkin's lymphoma remains poor and the treatment is palliative in the majority of the cases. Thus, the aim of this study was to present the results on the compassionate use of everolimus in a group of patients who were monitored at nine different centers in Brazil. METHODS: A 10-mg oral dose of everolimus was given to each patient daily. Response time was evaluated from the beginning of medication use until loss of response, toxicity or medical decision to cease treatment. RESULTS: Thirty-three patients were evaluated. The median age at the beginning of medication administration was 29 years. Patients had received a median of five prior therapies. Overall response rate was 45.4%, with 13 patients achieving partial response, two achieved clinical response, 14 remained with stable disease, two had disease progression, and two were not evaluated. Patients received a median of 14 cycles. Progression-free survival was nine months, and overall survival was estimated to be 36 months. Three patients used the medication for more than four years. The most frequently reported adverse events were thrombocytopenia and hypercholesterolemia. Three patients had pulmonary toxicity. Grade III and IV adverse events occurred in 39% of the patients. CONCLUSION: Everolimus was found to provide a response in a group of patients with refractory or relapsed Hodgkin's lymphoma who had adequate tolerability to the drug.
format Online
Article
Text
id pubmed-5567422
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Sociedade Brasileira de Hematologia e Hemoterapia
record_format MEDLINE/PubMed
spelling pubmed-55674222017-09-06 Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience Rocha, Talita Máira Bueno da Silveira da Fortier, Sergio Costa Fischer, Thais Rodrigues da Cunha Perini, Guilherme Fleury Gaiolla, Rafael Dezen Fogliatto, Laura Delamain, Marcia Torresan Costa, Andressa Fragoso da Castro, Nelson Siqueira de Barretos, Wolney Gois Souza, Cármino Antonio de Buccheri, Valéria Chiattone, Carlos Sérgio Rev Bras Hematol Hemoter Original Article BACKGROUND: Despite all the scientific progress that has been made on understanding the disease, prognosis for patients with relapsed and refractory Hodgkin's lymphoma remains poor and the treatment is palliative in the majority of the cases. Thus, the aim of this study was to present the results on the compassionate use of everolimus in a group of patients who were monitored at nine different centers in Brazil. METHODS: A 10-mg oral dose of everolimus was given to each patient daily. Response time was evaluated from the beginning of medication use until loss of response, toxicity or medical decision to cease treatment. RESULTS: Thirty-three patients were evaluated. The median age at the beginning of medication administration was 29 years. Patients had received a median of five prior therapies. Overall response rate was 45.4%, with 13 patients achieving partial response, two achieved clinical response, 14 remained with stable disease, two had disease progression, and two were not evaluated. Patients received a median of 14 cycles. Progression-free survival was nine months, and overall survival was estimated to be 36 months. Three patients used the medication for more than four years. The most frequently reported adverse events were thrombocytopenia and hypercholesterolemia. Three patients had pulmonary toxicity. Grade III and IV adverse events occurred in 39% of the patients. CONCLUSION: Everolimus was found to provide a response in a group of patients with refractory or relapsed Hodgkin's lymphoma who had adequate tolerability to the drug. Sociedade Brasileira de Hematologia e Hemoterapia 2017 2017-05-11 /pmc/articles/PMC5567422/ /pubmed/28830600 http://dx.doi.org/10.1016/j.bjhh.2017.03.008 Text en © 2017 Associaç˜ao Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Article
Rocha, Talita Máira Bueno da Silveira da
Fortier, Sergio Costa
Fischer, Thais Rodrigues da Cunha
Perini, Guilherme Fleury
Gaiolla, Rafael Dezen
Fogliatto, Laura
Delamain, Marcia Torresan
Costa, Andressa Fragoso da
Castro, Nelson Siqueira de
Barretos, Wolney Gois
Souza, Cármino Antonio de
Buccheri, Valéria
Chiattone, Carlos Sérgio
Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience
title Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience
title_full Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience
title_fullStr Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience
title_full_unstemmed Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience
title_short Everolimus as a single agent in refractory or relapsed Hodgkin's lymphoma: the Brazilian Named Patient Program Experience
title_sort everolimus as a single agent in refractory or relapsed hodgkin's lymphoma: the brazilian named patient program experience
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5567422/
https://www.ncbi.nlm.nih.gov/pubmed/28830600
http://dx.doi.org/10.1016/j.bjhh.2017.03.008
work_keys_str_mv AT rochatalitamairabuenodasilveirada everolimusasasingleagentinrefractoryorrelapsedhodgkinslymphomathebraziliannamedpatientprogramexperience
AT fortiersergiocosta everolimusasasingleagentinrefractoryorrelapsedhodgkinslymphomathebraziliannamedpatientprogramexperience
AT fischerthaisrodriguesdacunha everolimusasasingleagentinrefractoryorrelapsedhodgkinslymphomathebraziliannamedpatientprogramexperience
AT periniguilhermefleury everolimusasasingleagentinrefractoryorrelapsedhodgkinslymphomathebraziliannamedpatientprogramexperience
AT gaiollarafaeldezen everolimusasasingleagentinrefractoryorrelapsedhodgkinslymphomathebraziliannamedpatientprogramexperience
AT fogliattolaura everolimusasasingleagentinrefractoryorrelapsedhodgkinslymphomathebraziliannamedpatientprogramexperience
AT delamainmarciatorresan everolimusasasingleagentinrefractoryorrelapsedhodgkinslymphomathebraziliannamedpatientprogramexperience
AT costaandressafragosoda everolimusasasingleagentinrefractoryorrelapsedhodgkinslymphomathebraziliannamedpatientprogramexperience
AT castronelsonsiqueirade everolimusasasingleagentinrefractoryorrelapsedhodgkinslymphomathebraziliannamedpatientprogramexperience
AT barretoswolneygois everolimusasasingleagentinrefractoryorrelapsedhodgkinslymphomathebraziliannamedpatientprogramexperience
AT souzacarminoantoniode everolimusasasingleagentinrefractoryorrelapsedhodgkinslymphomathebraziliannamedpatientprogramexperience
AT buccherivaleria everolimusasasingleagentinrefractoryorrelapsedhodgkinslymphomathebraziliannamedpatientprogramexperience
AT chiattonecarlossergio everolimusasasingleagentinrefractoryorrelapsedhodgkinslymphomathebraziliannamedpatientprogramexperience